Clinical trials: Acute Exacerbation of Chronic Obstructive Airways Disease
- Condition Acute Exacerbation of Chronic Obstructive Airways Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive, Infections, Bacterial
Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD)
The aim of the study is to develop a new patient-reported outcome (PRO) questionnaire measuring the impact of an acute exacerbation on daily lives of patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00259909
- Testing
- GSK questionnaire, St. George's Respiratory Questionnaire, Acute Short Form 12 version 2
- Where
- 123 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
- Trial name
- NCT01332097
- Testing
- BCT197, Prednisone
- Where
- 6 sites in Bulgaria, Romania and 1 more
- Volunteers
- 183 people
- Sponsor
- Mereo BioPharma
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
COPD (Chronic Obstructive Pulmonary Disease)
COPD Exacerbation Follow Up
The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.
- Trial name
- NCT07118306
- Where
- 5 sites in United States
- Volunteers
- 485 people
- Sponsor
- Viz.ai, Inc.
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation
The purpose of this study is to evaluate specific alterations in immune cell mechanisms related to neutrophil function as detected by PI3Kdelta-dependent changes in messenger ribonucleic acid (mRNA) extracted from induced sputum…
- Trial name
- NCT02522299
- Testing
- GSK2269557, DISKUS, ELLIPTA
- Where
- 6 sites in Canada, Denmark
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Asthma Acute, COPD Exacerbation Acute
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
- Trial name
- NCT07705737
- Testing
- Rademikibart
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Connect Biopharm LLC
COPD
Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study
The aim of this study is to assess the effectiveness in preventing exacerbation of 52 weeks lysozyme administration in patients with COPD.
- Trial name
- NCT01645800
- Testing
- Lysozyme hydrochloride
- Where
- 25 sites in Japan
- Volunteers
- 408 people
- Sponsor
- Eisai Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
This is a Post-hoc analysis based on the database of "A non-interventional, retrospective study on AECOPD treatment status in China".
- Trial name
- CONTAIN (NCT03633838)
- Where
- China
- Volunteers
- 5,067 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations
The REVIVE Pivotal Study
The goal of this study is to test whether a new treatment called the Ryme Medical Targeted Lung Denervation (TLD) Catheter is safe and effective for people with moderate to severe chronic obstructive pulmonary disease (COPD).
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbations, COPD Patients, COPD Acute Exacerbation
- Trial name
- REVIVE (NCT07361653)
- Testing
- Ryme TLD
- Volunteers
- 300 people
- Sponsor
- Ryme Medical, Inc.
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Acute Exacerbation of COPD
Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD
This study evaluates the safety and efficacy of using the Hemolung RAS to provide low-flow extracorporeal carbon dioxide removal (ECCO2R) as an alternative or adjunct to invasive mechanical ventilation for patients who require…
- Trial name
- VENT-AVOID (NCT03255057)
- Testing
- Hemolung Respiratory Assist System, Invasive mechanical ventilation
- Where
- 32 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alung Technologies
Pulmonary Disease, Chronic Obstructive
Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in Japan
The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants
- Trial name
- NCT03957577
- Testing
- Prospective observational cohort study
- Where
- 13 sites in Japan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
Early Extubation by ECCO2R Compared to IMV in Patients with Severe Acute Exacerbation of COPD
The study aims to investigate if veno-venous (vv)-extracorporeal carbon dioxide Removal (ECCO2R) is capable of reducing mortality and/or severe disability at day 60 after randomisation in patients with severe acute exacerbation…
- Trial name
- X-COPD (NCT03584295)
- Testing
- Extracorporeal carbon dioxide removal, Conventional Care
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Xenios AG
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to…
- Trial name
- XYP-202401 (NCT06754865)
- Testing
- Xiyanping injection+ antibiotic, Antibiotic
- Volunteers
- 1,140 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
Vapendavir (VPV) is a drug being developed to treat human rhinovirus (RV) infection, one virus responsible for the common cold. Vapendavir prevents the virus from entering cells and making more infectious copies of itself.
- Conditions
- COPD Exacerbation Acute, COPD With Acute Lower Respiratory Infection, Rhinovirus, Virus Diseases
- Trial name
- NCT06149494
- Testing
- Vapendavir
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Altesa Biosciences, Inc.
Respiratory Failure, Neuromuscular Disease
Autotitrating Versus Standard Non-invasive Ventilation (NIV) in Acute Exacerbation of Respiratory Failure
The aim of the study is to compare the efficacy and tolerance of autotitrating non-invasive ventilation (NIV) versus standard NIV in patients admitted to hospital with acute exacerbation of chronic respiratory failure.
- Conditions
- Respiratory Failure, Neuromuscular Disease, Chest Wall Disorder, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01174316
- Testing
- AutoVPAP™, VPAPIIIST-A™
- Where
- United Kingdom
- Sponsor
- ResMed